H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Principia Biopharma (NASDAQ:PRNB) Inc on Friday, setting a price target of $77, which is approximately 23.20% above the present share price of $62.5.
Pantginis expects Principia Biopharma Inc to post earnings per share (EPS) of -$0.99 for the second quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Principia Biopharma, with an average price target of $76.75.
The analysts price targets range from a high of $80 to a low of $72.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$34.11 million. The company's market cap is $1.98 billion.
According to TipRanks.com, H.C. Wainwright analyst Joseph Pantginis is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.6% and a 50.66% success rate.
Principia Biopharma, Inc. is a biopharmaceutical company, which engages in design and development oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to purpose-design and develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline include PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 28, 2008 and is headquartered in South San Francisco, CA.